Noramco

7 articles about Noramco

• Noramco Announces Strategic Alignment with Purisys and Halo Pharma, Launching the Noramco Group as an Integrated North American-Based API and Drug Product Supply Chain Services Provider

  3/14/2024

  Noramco announced its launch of the Noramco Group, a newly created comprehensive North American-based supply chain solution including subsidiaries Purisys, Noramco, and the newly acquired drug product CDMO, Halo Pharma.

• Noramco Announces the Acquisition of the Cambrex Drug Product Business Unit

  11/2/2023

  Noramco, a leading global active pharmaceutical ingredients manufacturer, specializing in controlled substances, announced it has completed the acquisition of the Cambrex Drug Product Business Unit previously known as Halo Pharmaceuticals.

• Noramco Announces Submission of Drug Master File for Lisdexamfetamine Dimesylate ─ Active Pharmaceutical Ingredient

  12/3/2021

  Noramco, LLC today announced it has submitted a Type II Drug Master File (DMF) to the U.S. Food and Drug Administration (FDA) for the active pharmaceutical ingredient lisdexamfetamine dimesylate (Lisdex/LDX).

• Noramco Cannabinoids Business to Become Purisys

  9/19/2019

  Two Organizations Will Build on Strengths to Address Differentiated End-Use Markets

• Noramco and SPI Pharma Announce Availability of New Excipient Compatibility Study for Cannabidiol Solid Oral Dosage Forms

  7/9/2019

  Joint effort focuses on enhancing absorption, release profile, bioavailability and delivering higher CBD efficacy in convenient finished dosages

• Teewinot Life Sciences And Noramco Sign Letter Of Intent To Produce Cannabinoids With CannSynthesis Biocatalysis Technology

  3/20/2017

• Johnson & Johnson May Seek to Divest Itself of Noramco for $800 Million

  1/5/2016